Join us on Thursday, March 18^th for this NCPD-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Puma Biotechnology Inc.

Thursday, March 18, 2021
5:00 PM – 6:00 PM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

• Discussion of the clinical variables that guide the selection of specific therapeutic regimens for patients with HER2-overexpressing breast cancer (BC)
• Evaluation of the available data with existing HER2-targeted therapies and integration of recently approved agents into current treatment algorithms
• Recognition and management of the common and rare side effects associated with FDA-approved HER2-directed therapies in the care of patients with BC

Target Audience
This activity has been designed to meet the educational needs of registered nurses, nurse practitioners and clinical nurse specialists involved in the treatment of HER2-positive breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of specific therapeutic regimens for patients with HER2-overexpressing localized breast cancer, and use this information to counsel patients regarding personalized treatment decision-making.
• Apply available research evidence to individualize the selection and administration of adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
• Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, incorporating existing and recently approved targeted treatments.
• Appraise available research data leading to the recent FDA approval of trastuzumab deruxtecan for HER2-positive metastatic breast cancer, and identify patients who are appropriate candidates for treatment with this drug.
• Develop an understanding of the mechanism of action of and pivotal clinical trial findings with tucatinib in combination with trastuzumab and capecitabine for patients with previously treated HER2-positive breast cancer, and optimally integrate this novel regimen into treatment algorithms.
• Design an optimal approach to the clinical care of patients with HER2-positive breast cancer and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
• Recognize common and rare side effects associated with approved anti-HER2 agents, and devise supportive management plans for patients undergoing treatment for HER2-positive breast cancer.

Accreditation Statements
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Webinars/NCPD2021/HER2PositiveBC/Mar18/ILNA

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

FACULTY — Ms Carroll has no relevant conflicts of interest to disclose. The following faculty (and her spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Hurvitz – Consulting Agreement (Stock Investment): NKMax America; Contracted Research: Ambrx Inc, Amgen Inc, Arvinas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Dignitana, Genentech, a member of the Roche Group, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Sanofi Genzyme, Seagen Inc, Zymeworks; Paid Travel: Lilly; Stocks (Spouse): IDEAL IMPLANT, ROMTech.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Puma Biotechnology Inc.